

The STEAP1₂₆₂₋₂₇₀ Peptide Encapsulated into PLGA Microspheres Elicits Strong Cytotoxic T Cell Immunity in HLA-A*0201 Transgenic Mice—A New Approach to Immunotherapy Against Prostate Carcinoma

Valerie L. Herrmann,¹ Daniel E. Wieland,² Daniel F. Legler,³ Valentin Wittmann,²
and Marcus Groettrup^{1,3*}

¹*Division of Immunology, Department of Biology, University of Konstanz, Konstanz, Germany*

²*Department of Chemistry, University of Konstanz, Konstanz, Germany*

³*Biotechnology Institute Thurgau (BITg) at the University of Konstanz, Kreuzlingen, Switzerland*

BACKGROUND. PLGA microsphere-based vaccination has been proven to be effective in immunotherapy of syngeneic model tumors in mice. The critical step for the translation to humans is the identification of immunogenic tumor antigens and potent vaccine formulations to overcome immune tolerance.

METHODS. HLA-A*0201 transgenic mice were immunized with eight different human prostate cancer peptide antigens co-encapsulated with TLR ligands into PLGA microspheres and analyzed for antigen-specific and functional cytotoxic T lymphocyte responses.

RESULTS. Only vaccination with STEAP1₂₆₂₋₂₇₀ peptide encapsulated in PLGA MS could effectively crossprime CTLs in vivo. These CTLs recognized STEAP1₂₆₂₋₂₇₀/HLA-A*0201 complexes on human dendritic cells and prostate cancer cell lines and specifically lysed target cells in vivo. Vaccination with PLGA microspheres was much more potent than with incomplete Freund's adjuvant.

CONCLUSIONS. Our data suggests that there exist great differences in the immunogenicity of human PCa peptide antigens despite comparable MHC class I binding characteristics. Immunogenic STEAP1₂₆₂₋₂₇₀ peptide encapsulated into PLGA microspheres however was able to induce vigorous and functional antigen-specific CTLs and therefore is a promising novel approach for immunotherapy against advanced stage prostate cancer.

KEY WORDS: prostate cancer; tumor antigen; STEAP; cancer vaccine; PLGA microspheres

INTRODUCTION

With 233,000 new cases and 29,480 estimated deaths, prostate cancer (PCa) is the second-leading cause of cancer-related deaths in the United States in 2014 [1]. The majority of patients diagnosed with localized PCa are successfully treated with radiation therapy or radical prostatectomy [2,3]. However, within 10 years around 30% of patients eventually fail on local therapy and progress to advanced-stage or metastatic PCa. Androgen deprivation therapy is the standard care for patients with advanced PCa, although most tumors become resistant to primary

hormonal therapy within 14–30 months [4]. For men with metastatic castration resistant prostate

Grant sponsor: German Cancer Aid; Grant sponsor: Horizon 2020 NMP; Grant number: 686089 2 .

Conflict of interest: Nothing to declare.

*Correspondence to: Marcus Groettrup, Division of Immunology, Department of Biology, University of Konstanz, Konstanz 78457, Germany. E mail: marcus.groettrup@uni-konstanz.de

cancer (mCRPC) docetaxel chemotherapy in combination with prednisone was the only treatment option for more than a decade [5]. New agents, including abiraterone acetate, cabazitaxel, enzalutamide, and radium-223 dichloride were shown to prolong life for men with advanced PCa for several months [6–9]. The first approved cell-based immunotherapy, sipuleucel-T, afforded an increase of overall survival of 4.5 months [10]. This limited efficacy and high costs associated with *in vitro* loading of autologous antigen presenting cells fostered attempts to develop vaccination approaches relying on *in vivo* loading of antigen presenting cells (APCs) with antigen and immune stimulants. Such vaccination regimens might be combined with the administration of monoclonal antibodies blocking CTLA-4 and PD1 signaling that function as immune checkpoint inhibitors [11,12].

CD8⁺ cytotoxic T cells can efficiently recognize and destroy tumor cells which expose peptides derived from intracellular tumor-associated antigens (TAAs) in complex with MHC class I molecules on their surface [13]. These TAAs include proteins preferentially expressed in normal prostate tissue but are overexpressed in PCa. The first TAA for PCa was prostate-specific antigen (PSA), a kallikrein-like serine-protease that is almost exclusively expressed by prostate epithelial cells and can be detected in the majority of PCa tissues, and represents the most widely used serum marker for diagnosis and monitoring of PCa [14]. Another marker for normal prostate cells but also for the majority of prostate tumors, especially undifferentiated, metastatic PCa is the integral membrane glycoprotein prostate-specific membrane antigen (PSMA) [15]. Prostatic acid phosphatase (PAP) is a glycoprotein with enzymatic activity that is mainly secreted by prostate epithelial cells in benign and malignant prostate tissue [16]. Its main expression in the prostate and in more than 80% of primary PCa samples turns the glycosylphosphatidylinositol-anchored cell surface protein prostate stem cell antigen (PSCA) into an attractive antigen for immunotherapy, too [17,18]. Both transmembrane proteins, transient receptor potential melastatin 8 (TRPM8) and six-transmembrane epithelial antigen of the prostate 1 (STEAP1) are detectable in the majority of prostate tumors with TRPM8 being predominantly overexpressed in the first stages and lower grades of cancer [19] and the latter being detectable in different stages and metastases of PCa but also in a variety of other tumors, including bladder, colon, and ovarian cancer [20,21]. As an inhibitor of apoptosis, survivin is highly overexpressed in many human tumors, including PCa with its expression correlating with aggressiveness and poor prognosis [22].

On the basis of the crucial role of T cells in the elimination of tumor cells much attention has been paid to the identification of these TAAs and derived HLA class I-restricted T cell epitopes for the design of novel T cell-based immunotherapies. However, tumor cells develop from self-tissues, and therefore, the immune system is largely tolerant to them. The main objective of cancer immunotherapy thus is to strongly stimulate the immune system to boost the natural anti-tumor immunity [23]. We and other groups have investigated poly(D,L-lactide-co-glycolide) microspheres (PLGA MS) as antigen delivery system targeting dendritic cells (DCs) and macrophages *in vitro* and *in vivo* as an alternative to incomplete Freund's adjuvant (IFA) which has failed to be approved for routine clinical use [24–27]. Uptake of the antigens and TLR ligands encapsulated in PLGA MS by APCs does not negatively affect their cardinal properties like migratory capacity, cytokine secretion, and antigen presentation [28]. In addition, PLGA MS have beneficial properties like the protection of their content from degradation and the long-lasting depot effect for sustained and prolonged immune responses [29,30]. The addition of potent immune-enhancing adjuvants like cytosine-phosphorothioate-guanine oligodeoxynucleotides (CpG-ODN) or polyriboinosinic:polyribocytidylic acid (polyI:C) is necessary for the maturation and cross-priming ability of the APCs. For the generation of a potent immune response TLR ligand and antigen need to be co-encapsulated into the same PLGA MS to be targeted into the same endosome [31].

In this study, we examined the immunogenicity of eight different HLA-A*0201 restricted PCa peptide antigens. We show that despite similar encapsulation efficiencies and release profiles from PLGA MS and comparable binding characteristics to HLA-A*0201 only one out of the eight antigens was able to prime CTLs *in vivo*. These CTLs, however, were highly peptide-specific and fully functional, as they were able to specifically lyse target cells *in vivo*. In addition, the peptide specific CTLs were able to recognize the peptide/HLA*0201 complex both on human cells and prostate cancer cell lines and to elicit thereupon an immune response.

MATERIALS AND METHODS

Preparation of Microspheres

Microspheres (MS) were prepared from 14 kDa PLGA 50:50 carrying hydroxyl- and carboxyl-end groups (Resomer[®] RG502H, Evonik Röhm GmbH). The synthetic peptides PSA_{154–163}, PSCA_{14–22}, PAP_{112–120}, TRPM8_{187–195}, PSMA_{27–35}, Survivin_{96–104}, STEAP1_{86–94},

and STEAP1₂₆₂₋₂₇₀ from human prostate and TLR ligands were microencapsulated by spray drying as described elsewhere [32]. Briefly, 10 mg peptide and 5 mg CpG oligodeoxynucleotides with a phosphothioate backbone (CpG ODN 1826, Microsynth) or 0.5 mg polyI:C (Sigma–Aldrich) were dissolved in 0.5 ml 0.1 M NaHCO₃ and mixed with 1 g of PLGA dissolved in 20 ml dichloromethane. The aqueous and the organic phase were homogenized under ultrasonication for 10 sec on ice. The obtained w/o dispersion was immediately spray dried (Büchi, Mini Spray-Dryer 191) at a flow rate of 2 ml/min and inlet/outlet temperatures of 40°C/37°C. The obtained MS were washed out of the spray-dryer's cyclone with 0.05% poloxamer 188 (Synperonic® F68, Serva Electrophoresis), collected on a cellulose acetate membrane filter and dried under reduced pressure (20 mbar) for 18 hr at room temperature. MS were stored at 4°C. Immediately before use, MS were dispersed in PBS by ultrasonication for 30 sec to obtain a homogeneous MS suspension.

Mice and Immunizations

HLA-A*0201 transgenic mice (AAD mice [33]) were originally obtained from Charles River Laboratories. All mice were kept in a specific pathogen-free facility and used at 6–12 weeks of age. Animal experiments were approved by the Review Board of Regierungspräsidium Freiburg. Mice were immunized with a mixture of 5 mg peptide/CpG MS and 5 mg polyI:C MS or the respective amounts of peptide (50 µg), CpG-ODN (25 µg), and polyI:C (2.5 µg) emulsified in PBS:IFA (1:1). Control mice were treated with adjuvants MS corresponding to 5 mg CpG-ODN MS (25 µg) and 5 mg polyI:C MS (2.5 µg).

Characterization of the PLGA MS

To characterize the PLGA MS, encapsulation efficiency and release of the two peptides was analyzed. For the determination of the encapsulation efficiency, 5 mg MS were dissolved in 200 µl acetone. The solvent was evaporated with vacuum centrifugation and the pellet was resuspended in MilliQ water under ultrasonication. Release of the peptides from the PLGA MS was identified by dispersing 5 mg PLGA MS in 200 µl PBS by ultrasonication for 30 sec. After an incubation at 37°C under agitation for 6 days, samples were spun down. Peptide contents of the supernatants were determined using the MicroBCA™ Protein Assay Kit (Life Technologies) according to the manufacturer's protocol using the respective peptide as standard. Assessed amounts were compared to theoretical maximal loading and given in % encapsulation efficiency.

Peptide Binding Assay

Each peptide was tested for concentration-dependent HLA-A*0201 stabilization on T2 cells. T2 cells were washed twice in serum-free IMDM and incubated at room temperature overnight with the candidate peptides over a concentration range from 0.5 to 10 µM in the presence of 1 µg/ml β₂-microglobulin. T2 cells were washed twice and stained with an APC-conjugated anti-human HLA-A2 antibody clone BB7.2 (eBioscience). The peptide GILGFVFTL of influenza virus matrix1 protein residues 58–66, was used as positive control; incubation with PBS served as negative control. For the off-kinetics, T2 cells were incubated overnight at room temperature with 10 µM of the respective peptide followed by an incubation at 37°C in the presence of 50 µg/ml cycloheximide. After 1, 2, 3, 4, and 6 hr the loss of HLA-A*0201 molecules from the surface was monitored by flow cytometry.

Intracellular Cytokine Staining

Intracellular cytokine staining (ICS) was performed to detect intracellular interferon gamma (IFN-γ) as a measure of CTL activation. Splenocytes were isolated by mechanical disruption. The isolated cells were incubated with or without 10 µM of the respective peptide in the presence of 10 µM/ml brefeldin A for 5 hr at 37°C. After washing, the cells were stained with APC-conjugated rat anti-mouse CD8α antibody clone 53–6.7 (eBioscience) for 20 min at 4°C. The cells were washed twice before they were fixed with 4% paraformaldehyde in PBS for 5 min at 4°C. Afterwards, cells were washed twice with PBS/0.1% saponin for permeabilization and were then labeled intracellularly with FITC-conjugated rat anti-IFN-γ antibody clone XGM1.2 or FITC-conjugated rat IgG1 κ isotype control antibody in PBS/0.1% saponin overnight at 4°C. The next day, cells were washed twice and were resuspended in FACS buffer (PBS, 2% FCS, 2 mM EDTA, 2 mM NaN₃) for flow cytometry.

ELISPOT

A commercially available antibody pair (BD Biosciences) for the detection of IFN-γ producing cells was used according to the manufacturer's protocol. ELISPOT 96 well plates were coated with anti-IFN-γ antibody and subsequently blocked. Splenocytes were incubated with or without 10 µM of the respective peptide overnight at 37°C. After incubation with a biotinylated antibody for 2 hr, a streptavidin-alkaline phosphatase enzyme conjugate was added for 40 min at room temperature. Spots of the dried plate were

counted using an ImmunoScan instrument (C.T.L., Cellular Technology Ltd.).

Peptide/HLA-A*0201 Recognition Assay

Mice were immunized with a mixture of 5 mg STEAP₁₂₆₂₋₂₇₀/CpG MS and 5 mg polyI:C MS. After 6 days, splenocytes were isolated by mechanical disruption. The isolated splenocytes were co-incubated with STEAP₁₂₆₂₋₂₇₀ peptide or STEAP₁₂₆₂₋₂₇₀ presenting human HLA-A*0201 positive cells overnight. LNCaP, PC3 and DU154 were transiently transfected with pAADneo vector (kind gift of V.H. Engelhard, Charlottesville, VA) and maintained in RPMI 1640 supplemented with 10% FCS, 1% P/S and 500 µg/ml geneticin G418. Transfected cell lines were screened and sorted for AAD expression by flow cytometry using the APC-conjugated anti-human HLA-A2 antibody clone BB7.2 (eBioscience). Ninety-five percent of the PC3 cells and 82% of the LNCaP and DU154 cells expressed AAD 2 days after the sort and are referred to as PC3-AAD, LNCaP-AAD, DU154-AAD. These transfectants or T2 cells were incubated at 37°C for 1 hr with or without 10⁻⁶ M STEAP₁₂₆₂₋₂₇₀ peptide, washed twice and then used for the recognition assay. Human monocyte-derived dendritic cells (MoDCs) were generated from peripheral blood mononuclear cells (PBMC) as previously described [34]. In brief, heparinized blood was taken from HLA-A*0201 positive donors to obtain PBMC by density gradient centrifugation on Ficoll-Paque1 at 1,800 rpm for 20 min. After magnetic sorting for CD14⁺ monocytes (Miltenyi Biotec), cells were further cultured for 5 days in AIM-V containing 1,000 U/ml of GM-CSF and 800 U/ml of IL-4. On day 5, 0.25 mg STEAP₁₂₆₂₋₂₇₀/CpG MS or CpG MS were added to 1 × 10⁶ immature MoDCs. After 2 days of maturation, MoDCs were washed twice and were then used for the recognition assay. Analysis was performed by ELISPOT assay or ELISA for IFN-γ.

ELISA

For the detection of IFN-γ secretion by PLGA MS induced CTLs, supernatants of the recognition assay were analyzed using a mouse IFN-γ ELISA kit (BD Biosciences) according to the manufacturer's instructions.

In Vivo Cytotoxicity Assay

For the analysis of the cytotoxic activity of CTLs in vivo, splenocytes from naïve mice were depleted from erythrocytes. Half of the cells was left untreated, the other half was pulsed with

10⁻⁶ M peptide for 1 hr at 37°C. Afterwards, untreated and peptide pulsed cells were stained with 1 µM/10 µM CFSE, respectively, for 10 min at 37°C. A mixture of 1 × 10⁷ pulsed and unpulsed cells in a total volume of 200 µl was injected i.v. in the tail vein of mice that were immunized with peptide/CpG MS and 5 mg polyI:C MS or control mice that received 5 mg CpG MS and 5 mg polyI:C MS 5 days before. After 24 hr splenocytes and liver lymphocytes of the immunized mice were analyzed for CFSE-labeled cells by flow cytometry. Splenocytes were isolated by mechanical disruption of the spleen. For isolation of liver lymphocytes, the liver was cut into small pieces and digested at 37°C in IMDM containing 0.2 mg/ml of collagenase D (Roche), 0.2 mg/ml of DNase I (Roche), 10% FCS, 100 U/ml P/S for 45 min at 37°C under agitation. Cells were gently pressed through a mesh, washed and re-suspended in 36% Percoll[®] in PBS (Sigma-Aldrich). The cell suspension was gently overlaid onto 70% Percoll[®] and centrifuged for 30 min at 1350 × g at 4°C. Lymphocytes were collected from the interface. The percentage of specific cytotoxicity was calculated as follows: 100 - [(% peptide pulsed cells in vaccinated mice / % unpulsed cells in vaccinated mice) / (% peptide pulsed cells in control mice / % unpulsed cells in control mice)] × 100.

Statistics

For statistical analyses, groups from similar experiments were pooled and analyzed for significant differences as indicated in the graph. The *P*-values for experiment composites are given in the figure legends. All the statistical analyses were performed using Prism software (GraphPad Software, Inc.).

RESULTS

PCa Peptide Antigens are Efficiently Encapsulated and Released From PLGA MS

Characterization of the PLGA MS containing the eight PCa antigens PSA₁₅₄₋₁₆₃, PSCA₁₄₋₂₂, PAP₁₁₂₋₁₂₀, TRPM8₁₈₇₋₁₉₅, PSMA₂₇₋₃₅, Survivin₉₆₋₁₀₄, STEAP₁₈₆₋₉₄, and STEAP₁₂₆₂₋₂₇₀ revealed that all peptide antigens could be encapsulated into the PLGA MS (Fig. 1, black bars). In addition, all the peptides were released from the microspheres in PBS (Fig. 1, white bars). The time interval for the release in aqueous medium mimics the time span of 6 days between immunization and analysis used in our in vivo immunization protocol. Furthermore, no overt differences in encapsulation efficiency and release were observable between the eight different PCa peptide antigens.




Fig. 1. Characterization of PLGA encapsulated prostate carcinoma antigens by in vitro release. Encapsulation efficiency and release during 6 days in aqueous medium of peptide/CpG containing PLGA MS as determined by BCA assay. Assessed amounts of peptide were compared to theoretical maximal loading and given in percent encapsulation efficiency. The experiment has been repeated twice with similar outcome.

PCa Peptide Antigens Bind and Stabilize HLA-A*0201

One of the most important features of a peptide antigen is a strong binding and thus stabilization of MHC class I molecules. In silico analysis with the publically available epitope prediction programs SYFPEITHI (<http://www.syfpeithi.de/>) and BIMAS (http://www-bimas.cit.nih.gov/molbio/hla_bind/) assigned excellent binding properties to all eight peptide antigens for HLA-A*0201. Stabilization of the HLA-A*0201 peptide complex on the cell surface was compared to the immunodominant, high affinity HLA-A*0201 ligand influenza virus matrix peptide M1₅₈₋₆₆. Like the M1 reference peptide, PSCA₁₄₋₂₂ and PSMA₂₇₋₃₅ stabilized HLA-A*0201 even at concentrations below 0.5 μ M (Fig. 2). All of the other antigens were also able to stabilize HLA-A*0201 already at low concentrations. PSA₁₅₄₋₁₆₃ and Survivin₉₆₋₁₀₄ were the only epitopes that could not stabilize HLA-A*0201 as efficiently. In conclusion, all of the eight PCa peptide antigens can stabilize the HLA-A*0201 complex on the cell surface with low off rates.

Superior Induction of a STEAP1₂₆₂₋₂₇₀-Specific CTL Response by Immunization of HLA-A*0201 Transgenic Mice With PLGA MS as Compared to IFA

Immunogenicity of the eight different PCa peptide antigens was assayed in vivo using AAD mice [33]. AAD mice express a transgene encoding an MHC class I fusion protein consisting of the peptide binding α 1 and α 2 domain of human HLA-A*0201 and the CD8 binding α 3 domain of mouse H-2D^d. Corresponding amounts of PCa peptide as well as of the

adjuvants CpG-ODN and polyI:C were either encapsulated into PLGA MS or emulsified in IFA. Vaccination with STEAP1₂₆₂₋₂₇₀, both in PLGA MS and IFA, induced peptide specific CTLs. A brief restimulation of these CTLs with STEAP1₂₆₂₋₂₇₀ peptide in vitro triggered a robust IFN- γ response, which was significantly higher for the PLGA MS compared to IFA (Fig. 3A,B). Vaccination with only the adjuvants CpG-ODN and polyI:C encapsulated into PLGA MS served as negative control. Restimulation of the splenocytes from these control mice with STEAP1₂₆₂₋₂₇₀ peptide induced no IFN- γ response. Surprisingly, vaccination with PSA₁₅₄₋₁₆₃, PSCA₁₄₋₂₂, PAP₁₁₂₋₁₂₀, TRPM8₁₈₇₋₁₉₅, PSMA₂₇₋₃₅, Survivin₉₆₋₁₀₄, and STEAP1₈₆₋₉₄ peptides co-encapsulated with CpG-ODN in PLGA MS and co-administered with polyI:C PLGA MS induced no peptide specific CTLs. This lack of a detectable CTL response was not only observed after PLGA MS-based vaccination but also when mice were vaccinated with the same peptides emulsified in IFA (Fig. 3A,B). The failure to elicit CTL responses for these seven PCa peptide antigens could, therefore, not be attributed to problems with PLGA MS specific encapsulation or release but most likely to marginal immunogenicity of these PCa peptide antigens in AAD mice.

PLGA MS Induced CTLs Specifically Lyse Peptide-Loaded Target Cells In Vivo

Next, the functionality of the generated STEAP1₂₆₂₋₂₇₀ specific CTLs in terms of their ability to lyse target cells in a peptide-specific manner was assayed. For vaccination with STEAP1₂₆₂₋₂₇₀/CpG MS and polyI:C MS the in vivo cytotoxicity assay showed robust responses. At day 6 after immunization STEAP1₂₆₂₋₂₇₀ pulsed target were specifically lysed both in spleen and liver whereas unpulsed

Peptide	Sequence	Concentration to stabilize MHC [μ M]	Off-kinetics [h]
FluM1 ₅₈₋₆₆	GILGFVFTL	< 0.5	>> 6
PSA ₁₅₄₋₁₆₃	VISNDVCAQV	2	3
PSCA ₁₄₋₂₂	ALQPGTALL	< 0.5	>> 6
PAP ₁₁₂₋₁₂₀	TLMSAMTNL	1	>> 6
TRPM8 ₁₈₇₋₁₉₅	GLMKYIGEV	1	>> 6
PSMA ₂₇₋₃₅	VLAGGFLL	< 0.5	>> 6
Survivin ₉₆₋₁₀₄	LTLGEFLKL	1	3
STEAP1 ₈₆₋₉₄	FLYTLLREV	1	>> 6
STEAP1 ₂₆₂₋₂₇₀	LLLGTIHAL	1	>> 6

Fig. 2. HLA A*0201 binding characteristics of the PCa peptide epitopes. For the stability assay, T2 cells were incubated at room temperature overnight with the indicated peptides over a range of peptide concentrations from 0.5 to 10 μ M in the presence of 1 μ g/ml β_2 microglobulin. The concentrations of the respective peptides needed to stabilize HLA A*0201 on the cell surface are provided. For the off kinetics, T2 cells were incubated overnight in the presence of 10 μ M peptide, followed by an incubation at 37°C in the presence of 50 μ g/ml cycloheximide. Loss of HLA A*0201 molecules from the cell surface (off kinetics) was monitored by flow cytometry after 1, 2, 3, 4, and 6 hr, respectively, as compared to cells incubated without peptide. The experiments have been performed twice with similar outcome.

control cells were not affected in the same mice (Fig. 4). In control mice immunized with CpG MS and polyI:C MS neither the peptide pulsed nor the unpulsed cells were lysed. In conclusion, CTLs induced by vaccination with PLGA MS containing STEAP1₂₆₂₋₂₇₀ were not only able to elicit an IFN- γ response upon restimulation (Fig. 3) but also killed the target cells in a peptide-specific manner (Fig. 4). In contrast, CTLs of mice that were immunized with TRPM8₁₈₇₋₁₉₅/CpG MS and polyI:C MS did not lyse TRPM8₁₈₇₋₁₉₅ pulsed target cells, which is consistent with the finding that specific CTL responses could not be elicited after PLGA MS or IFA based vaccination (Fig. 3).

PLGA MS Induced CTLs Recognize Human HLA-A*0201/STEAP1₂₆₂₋₂₇₀ Complexes

The first signal for the activation of primed T cells is provided through the T-cell receptor which interacts with peptide/MHC complexes on the surface of antigen presenting cells. Therefore, CTLs induced by vaccination with PLGA MS, including STEAP1₂₆₂₋₂₇₀ should recognize and respond to human APCs presenting STEAP1₂₆₂₋₂₇₀ peptide on HLA-A*0201. Indeed, splenocytes of vaccinated mice did not only respond upon peptide restimulation but also recognized and responded to peptide pulsed human

prostate cancer cell lines LNCaP, PC3, and DU154 transfected with AAD and human HLA-A*0201 positive T2 cells (Fig. 5). Peptide specificity was analyzed by comparison to stimulation with unpulsed cells, which resulted in a significantly lower IFN- γ release. The same result was observable for CTL stimulation with human monocyte-derived dendritic cells (MoDCs) raised from HLA-A*0201 positive donors after uptake of STEAP1₂₆₂₋₂₇₀/CpG MS leading to maturation of the MoDCs and to HLA-A*0201-mediated peptide presentation on the cell surface. Stimulation with mature MoDCs after CpG MS uptake induced significantly less IFN- γ producing CTLs. These data show that STEAP1₂₆₂₋₂₇₀ specific CTLs raised in HLA-A*0201/H-2D^d chimera expressing AAD mice recognize this peptide also on human HLA-A*0201 and that human MoDC can be readily charged with the STEAP1₂₆₂₋₂₇₀ peptide by PLGA MS.

DISCUSSION

T-cell based immunotherapy of cancer is a promising non-invasive option for treatment of minimal residual disease, prevention of metastatic spread, and delay of recurrence without compromising quality of life. One of the major obstacles is the identification of possible antigenic peptide epitopes that are capable of initiating effective anti-tumor T-cell responses.




Fig. 3. Comparison of the CTL response after immunization with PLGA MS or IFA. Male HLA A*0201 transgenic AAD mice (n = 3) were immunized with 5 mg peptide/CpG MS and 5 mg polyI:C MS per mouse (containing 50 μ g peptide, 25 μ g CpG, 2.5 μ g polyI:C). Alternatively, equivalent amounts of peptide, CpG, and polyI:C were emulsified in IFA and used for vaccination. As control, adjuvants containing MS (Adj) incorporating only CpG and polyI:C were used. On day 6 after immunization splenocytes were isolated and analyzed for peptide specific CD8⁺ T cell responses by intracellular cytokine staining (ICS) for IFN γ and flow cytometry (**A**) as well as ELISPOT assay (**B**). Representative examples of dot plots of the indicated ICS experiments are shown in (**A**) below the graph. Background levels (no peptide) were subtracted. Values (mean \pm SEM) in (**A**) are given in percent IFN γ ⁺ of CD8⁺ lymphocytes. The P values of (**A**) were calculated by an unpaired t test with Welsch's correction (*P = 0.0218; *P = 0.0108). Values (mean \pm SEM) in (**B**) are given as IFN γ specific spots/well. The P value was calculated by an unpaired t test with Welsch's correction (*P = 0.0233). The experiments have been performed three times with similar outcome.




Fig. 4. CTL mediated in vivo cytotoxicity elicited by vaccination with PLGA MS. Male HLA A*0201 transgenic AAD mice (n = 6) were immunized with 5 mg STEAP1₂₆₂₋₂₇₀/CpG MS or TRPM8₁₈₇₋₁₉₅/CpG MS and 5 mg polyI:C MS per mouse (containing 50 µg peptide, 25 µg CpG, 2.5 µg polyI:C). As controls adjuvants microspheres bearing respective amounts of CpG and polyI:C were used. On day 6 after immunization splenocytes from naïve mice were depleted from erythrocytes. Half of the cells was left untreated, the other half was pulsed with 10⁻⁶ M of the respective peptide for 1 hr at 37°C. Afterwards, untreated and peptide pulsed cells were stained with 1 µM/10 µM CFSE, respectively. A mixture of 1 × 10⁷ pulsed and unpulsed cells was injected i.v. in the tail vein of the immunized mice. After 24 hr splenocytes and liver lymphocytes of the immunized mice were analyzed for CFSE labeled cells by flow cytometry. Representative examples of flow cytometry histograms of CFSE labeled target cells from the mice immunized as indicated are shown below the graph. Values (mean ± SEM) are given in percent specific lysis. The P value was calculated by an unpaired t test with Welsch's correction (**P = 0.0008; ****P = <0.0001). The experiments have been performed three time with similar results.




Fig. 5. STEAPI₂₆₂₋₂₇₀/HLA A*0201 recognition on PLGA MS pulsed human dendritic and prostate carcinoma cells by peptide specific CTLs. Male HLA A*0201 transgenic AAD mice ($n = 6$) were immunized with 5 mg STEAPI₂₆₂₋₂₇₀/CpG MS and 5 mg polyI:C MS per mouse. On day 6 after immunization splenocytes were isolated and stimulated by addition of either +/− STEAPI₂₆₂₋₂₇₀ peptide alone (peptide), by (A,B) LNCaP AAD, PC3 AAD, DU154 AAD cells externally pulsed or not with STEAPI₂₆₂₋₂₇₀ peptide or (C) T2 cells externally pulsed or not with STEAPI₂₆₂₋₂₇₀ peptide, or by human HLA A*0201⁺ MoDC charged with CpG MS alone or with STEAPI₂₆₂₋₂₇₀/CpG MS. Peptide specific CD8⁺ T cell responses were detected in (B) by ELISA for IFN γ in the supernatant; values (mean \pm SEM) are given as pg/ml IFN γ . The P values were calculated by an unpaired t test (** $P = 0.0010$; *** $P = 0.0046$). In A and C, IFN γ secretion of the CTLs was detected by ELISPOT assays. Values (mean \pm SEM) are given as IFN γ specific spots/well. The P values were calculated by an unpaired t test with Welch's correction B:(** $P = 0.0155$; **** $P = <0.0001$; * $P = 0.0104$)/C:(** $P = 0.0010$; *** $P = 0.0002$; * $P = 0.0241$). The experiments have been performed two times with similar outcome.

Ideal target epitopes are exclusively expressed in nonvital tissues, highly expressed in metastatic disease and accessible to therapeutic modalities [35]. All eight PCa epitopes used in this study scored very well for in silico predictions of HLA-A*0201 binding. Positive prognosis for their potential as antigenic epitopes by “reverse immunology” approaches was confirmed by the characterization of the HLA-A*0201 binding properties using the HLA-A*0201 positive human T2 cell line (Fig. 2). The efficacy of tumor immunotherapy is highly dependent on breaking the

tolerance of the specific CD8⁺ T cell repertoire against the non-mutated self-tumor antigens [36]. Furthermore, cancer often coincides with an immunosuppressive microenvironment within and around the tumor, characterized by the prevalence of immunosuppressive cytokines and high infiltration of regulatory T cells [37,38]. TLR agonists are being widely used to break immunological tolerance towards autologous TAAs and activate anti-cancer immune responses [39,40]. The utilization of CpG-ODN and polyI:C in our immunizations generates a strong Th1

	murine epitope	human epitope	Grand average of hydrophaticity
PSA ₁₅₄₋₁₆₃	lisndvcNqv *	visndvcaqv	1.010
PSCA ₁₄₋₂₂	alHpgAalQ	alqpgtall	0.978
PAP ₁₁₂₋₁₂₀	tlmsamtnl	tlmsamtnl	0.833
TRPM8 ₁₈₇₋₁₉₅	glmkyigev	glmkyigev	0.544
PSMA ₂₇₋₃₅	vlaLTGTFI	vlaggfll	2.467
Survivin ₉₆₋₁₀₄	ltVseflkl	ltlgeflkl	1.056
STEAP1 ₈₆₋₉₄	flytllrel	flytllrev	0.933
STEAP1 ₂₆₂₋₂₇₀	lllgtVhal	lllgtihal	1.911

* transmembrane protease serine 11G

Fig. 6. Properties of the PCa epitopes. Comparison of the human PCa epitopes with their murine homologues. Non identical amino acids are marked with capital letters. The grand average hydrophaticity was calculated as sum of the hydrophathy values of all amino acids based on the Kyte Doolittle scale.

polarizing condition, which in combination with the usage of a peptide exclusively presented on HLA-A*0201 to CD8⁺ cytotoxic T cells, counteracts an unwanted Treg induction.

In the last decade, much work has been devoted to the investigation of DC-based immunotherapies. However, cultivation and antigen pulse of human DCs in vitro and injection of these cells into patients is a very labor and cost intensive approach which in addition yielded largely disappoint results [41–44]. The ideal tool for the improvement of DC-based immunotherapies is the usage of PLGA MS as antigen delivery system. PLGA MS are rapidly and efficiently taken up by immature dendritic cells in vitro and in vivo and release the encapsulated contents intracellularly in a sustained manner for processing and presentation on MHC class I and II molecules [28,30,45]. All PCa tumor antigens used in this study could be efficiently encapsulated into PLGA MS and were released during incubation in an aqueous environment (Fig. 1). Another antigen delivery system that has been used in numerous studies is incomplete Freund's adjuvant (IFA), a water-in-oil emulsion that can be mixed with antigens and pattern molecules. However, IFA has—in contrast to PLGA MS—some severe side effects like local skin irritations, inflammations, sterile abscesses, and cysts as well as persistent painful granulomas at the site of injection [46].

In our study, we showed that PLGA MS were even superior to IFA-based vaccination with STEAP1₂₆₂₋₂₇₀ peptide antigen and the TLR ligands CpG ODN and polyI:C in HLA-A*0201 transgenic AAD mice (Fig. 3). Unexpectedly, for all the other PCa antigen epitopes tested in this study neither PLGA MS nor IFA were

able to induce peptide-specific CTLs. This result cannot be attributed to differences in the quality or purity of the used peptides as their identity was confirmed by mass spectrometry and their purity by HPLC analysis (data not shown). Moreover, only the PSA₁₅₄₋₁₆₃ peptide contains a cysteine which can be oxidized over time and hence become less immunogenic (Fig. 6). The immunogenic STEAP1₂₆₂₋₂₇₀ peptide has a high hydrophaticity score (listed in Fig. 6) but so does PSMA₂₇₋₃₅ which did not yield a CTL response in AAD mice. Yu et al. suggested that poor immunogenicity of self/tumor antigens derives from peptide/MHC-I instability rather than from tolerance [47], which we consider unlikely for these antigens as they all provide good HLA-A*0201 binding and stabilization characteristics (Fig. 2). As some of the antigens like PAP₁₁₂₋₁₂₀ display complete and others like PSMA₂₇₋₃₅ only minor conservation between human and mouse sequences neither the induction of xeno-CTLs nor self-tolerance seems to play a crucial role for the immunogenicity of the peptides (Fig. 6). The sole immunogenic epitope STEAP1₂₆₂₋₂₇₀ differs only in one conserved amino acid between the murine epitope (LLLGTVHAL) and its human homologue (LLLGTIHAL) used in this study. CTLs raised against human STEAP1₂₆₂₋₂₇₀ have even been shown to cross-react with mouse STEAP1₂₆₂₋₂₇₀ [48]. This suggests that a reduced tolerance induction against the human STEAP1₂₆₂₋₂₇₀ epitope in AAD mice cannot explain the superior CTL response to this peptide (Fig. 3). One could argue that the exclusive response to STEAP1₂₆₂₋₂₇₀ in AAD mice is due to a much higher CTL precursor frequency in the T cell repertoire of these mice. While a bias in the T cell repertoire can certainly contribute to this

phenomenon, it seems unlikely that CTL precursors specific for seven other PCa epitopes are lacking in AAD mice given that they react to numerous other HLA-A*0201 epitopes [33]. Since the T cell repertoire in humans likely varies among individuals this parameter cannot easily be taken into consideration. Of note, the CTL response to the STEAP1₂₆₂₋₂₇₀ epitope was HLA-A*0201 specific as no immune response was detectable after immunization of C57BL/6 mice (data not shown). Vaccination with peptide epitopes obviously excludes the possibility of differences in antigen processing efficiencies, too.

Machlenkin et al. previously reported on the CTL inducing capability of a cell-based prime-boost vaccination with STEAP1₂₆₂₋₂₇₀ peptide-pulsed DCs in HLA-A2.1/H-2D^b-β₂microglobulin monochain transgenic HHD mice in vivo and peptide induced CTL activity in vitro [48]. In agreement with these results, we were able to monitor in vivo cytolytic activity of the peptide specific CTLs, but already after a single vaccination with peptide-loaded PLGA MS (Fig. 4). The STEAP1₂₆₂₋₂₇₀ response elicited by MS was so strong, that its detection by IFN-γ ICS or ELISPOT did not require CTL expansion by in vitro restimulation. Previously, it was shown that a CTL line specific for a modified version of another epitope of STEAP1 (STEAP1₂₉₂₋₃₀₀) could recognize HLA-A*0201⁺ and STEAP1⁺ prostate cancer and other cell lines after in vitro restimulation [35]. We could show that STEAP1₂₆₂₋₂₇₀ specific CTLs, after a single immunization with PLGA MS containing the epitope, were not only able to recognize the epitope presented on HLA-A*0201 by T2 Lymphoblastoid cells and by three different human cancer cell lines on AAD but also on human MoDCs that present the epitope after PLGA MS uptake. STEAP1 is an ideal target for cancer immunotherapy as it is strongly expressed in multiple tumor types like prostate cancer, melanoma, colon cancer and Ewing's sarcoma, it has a restricted expression in normal tissues and cell surface localization [35]. Its localization at the cell-cell junctions of the secretory epithelium taken together with the six-transmembrane topology, suggests a function of STEAP1 as channel/transporter protein in cell-cell junctions and an involvement in tumor growth [21] which may render an elimination of STEAP1 from PCa cells less likely.

CONCLUSIONS

We have shown that STEAP1₂₆₂₋₂₇₀ is the only out of eight possible antigenic peptide epitopes that was immunogenic enough to induce antigen specific CTLs after a single immunization with PLGA MS incorporating the peptide and the TLR ligand CpG ODN and polyI:C MS. It will now be attractive to test the PLGA

MS-based immunization against STEAP1₂₆₂₋₂₇₀ in pre-clinical models of PCa. As STEAP1 peptide can be produced in large scale and PLGA is a material approved for clinical application, immunotherapy of PCa with STEAP1₂₆₂₋₂₇₀ encapsulated into PLGA MS is a feasible, reproducible, and cost-effective approach which deserves to be developed for clinical testing in humans.

ACKNOWLEDGMENTS

Ilona Kindinger is acknowledged for experimental advice for MoDC preparation. We thank the personnel of the animal research facility of Konstanz University and Stefanie Buerger of the flow cytometry facility FlowKon. V.H. is a member of the DFG Research Training Group 1331 and D.E.W. is a member of the Konstanz Research School Chemical Biology. This project was funded by the German Cancer Aid and the Horizon 2020-NMP program of the European Commission, project Nr. 686089-2 (Precious).

REFERENCES

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. *CA Cancer J Clin* 2014;64(1):9-29.
2. Coen JJ, Zietman AL, Thakral H, Shipley WU. Radical radiation for localized prostate cancer: Local persistence of disease results in a late wave of metastases. *J Clin Oncol* 2002;20(15):3199-3205.
3. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long term results. *J Urol* 2004;172(3):910-914.
4. Risk M, Corman JM. The role of immunotherapy in prostate cancer: An overview of current approaches in development. *Rev Urol* 2009;11(1):16-27.
5. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. *N Engl J Med* 2004;351(15):1502-1512.
6. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration resistant prostate cancer progressing after docetaxel treatment: A randomised open label trial. *Lancet* 2010;376(9747):1147-1154.
7. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Pitulats JM, Ng S, Carles J, Mulders PFA, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttman H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin M E, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE. Abiraterone in metastatic prostate cancer without previous chemotherapy. *N Engl J Med* 2013;368(2):138-148.
8. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS. Increased survival

- with enzalutamide in prostate cancer after chemotherapy. *N Engl J Med* 2012;367(13):1187-1197.
9. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzen L, Coleman R, Vogelzang NJ, O'Bryan Tear CG, Staudacher K, Garcia Vargas J, Shan M, Bruland OS, Sartor O. Alpha emitter radium 223 and survival in metastatic prostate cancer. *N Engl J Med* 2013;369(3):213-223.
 10. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM. Placebo controlled phase III trial of immunologic therapy with sipuleucel T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. *J Clin Oncol* 2006;24(19):3089-3094.
 11. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. *N Engl J Med* 2011;364(26):2517-2526.
 12. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL. Phase I study of single agent anti programmed death 1 (MDX 1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. *J Clin Oncol* 2010;28(19):3167-3175.
 13. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. *Immunol Today* 1997;18(4):175-182.
 14. Oesterling JE. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. *J Urol* 1991;145(5):907-923.
 15. Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. *Cancer* 1998;83(11):2259-2269.
 16. Solin T, Kontturi M, Pohlmann R, Vihko P. Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): Evaluation by RNA blot analyses. *Biochim Biophys Acta* 1990;1048(1):72-77.
 17. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, Loda M, Witte ON. Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer. *Proc Natl Acad Sci USA* 1998;95(4):1735-1740.
 18. Dannull J, Diener PA, Prikler L, Furstenberger G, Cerny T, Schmid U, Ackermann DK, Groettrup M. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. *Cancer Res* 2000;60(19):5522-5528.
 19. Tsavaler L, Shaper MH, Morkowski S, Laus R. Trp p8, a novel prostate specific gene, is up regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. *Cancer Res* 2001;61(9):3760-3769.
 20. Hubert RS, Vivanco I, Chen E, Rastegar S, Leong K, Mitchell SC, Madraswala R, Zhou Y, Kuo J, Raitano AB, Jakobovits A, Saffran DC, Afar DE. STEAP: a prostate specific cell surface antigen highly expressed in human prostate tumors. *Proc Natl Acad Sci USA* 1999;96(25):14523-14528.
 21. Challita Eid PM, Morrison K, Eteessami S, An Z, Morrison KJ, Perez Villar JJ, Raitano AB, Jia XC, Gudas JM, Kanner SB, Jakobovits A. Monoclonal antibodies to six transmembrane epithelial antigen of the prostate 1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo. *Cancer Res* 2007;67(12):5798-5805.
 22. Koike H, Sekine Y, Kamiya M, Nakazato H, Suzuki K. Gene expression of survivin and its spliced isoforms associated with proliferation and aggressive phenotypes of prostate cancer. *Urology* 2008;72(6):1229-1233.
 23. Escors D. Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy. *New J Sci* 2014; doi: 10.1155/2014/734515
 24. Waeckerle Men Y, Groettrup M. PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. *Adv Drug Deliv Rev* 2005;57(3):475-482.
 25. Malyala P, O'Hagan DT, Singh M. Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable micro particles. *Adv Drug Deliv Rev* 2009;61(3):218-225.
 26. Akagi T, Wang X, Uto T, Baba M, Akashi M. Protein direct delivery to dendritic cells using nanoparticles based on amphiphilic poly(amino acid) derivatives. *Biomaterials* 2007;28(23):3427-3436.
 27. Mueller M, Schlosser E, Gander B, Groettrup M. Tumor eradication by immunotherapy with biodegradable PLGA microspheres an alternative to incomplete Freund's adjuvant. *Int J Cancer* 2011;129(2):407-416.
 28. Waeckerle Men Y, Scandella E, Uetz Von Allmen E, Ludewig B, Gillessen S, Merkle HP, Gander B, Groettrup M. Phenotype and functional analysis of human monocyte derived dendritic cells loaded with biodegradable poly(lactide co glycolide) microspheres for immunotherapy. *J Immunol Methods* 2004;287(1-2):109-124.
 29. Audran R, Peter K, Dannull J, Men Y, Scandella E, Groettrup M, Gander B, Corradin G. Encapsulation of peptides in biodegradable microspheres prolongs their MHC class I presentation by dendritic cells and macrophages in vitro. *Vaccine* 2003;21(11):1250-1255.
 30. Waeckerle Men Y, Allmen EU, Gander B, Scandella E, Schlosser E, Schmidtke G, Merkle HP, Groettrup M. Encapsulation of proteins and peptides into biodegradable poly(D,L lactide co glycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells. *Vaccine* 2006;24(11):1847-1857.
 31. Schlosser E, Mueller M, Fischer S, Basta S, Busch DH, Gander B, Groettrup M. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. *Vaccine* 2008;26(13):1626-1637.
 32. Waeckerle Men Y, Gander B, Groettrup M. Delivery of tumor antigens to dendritic cells using biodegradable microspheres. *Methods Mol Med* 2005;109:35-46.
 33. Newberg MH, Smith DH, Haertel SB, Vining DR, Lacy E, Engelhard VH. Importance of MHC class 1 alpha2 and alpha3 domains in the recognition of self and non self MHC molecules. *J Immunol* 1996;156(7):2473-2480.
 34. Waeckerle Men Y, Allmen EU, von Moos R, Classon BJ, Scandella E, Schmid H P, Ludewig B, Groettrup M, Gillessen S. Dendritic cells generated from patients with androgen independent prostate cancer are not impaired in migration and T cell stimulation. *The Prostate* 2005;64(4):323-331.
 35. Rodeberg DA, Nuss RA, ElSawa SF, Celis E. Recognition of six transmembrane epithelial antigen of the prostate expressing

- tumor cells by peptide antigen induced cytotoxic T lymphocytes. *Clin Cancer Res* 2005;11(12):4545-4552.
36. Bai XF, Liu J, Li O, Zheng P, Liu Y. Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes. *J Clin Invest* 2003;111(10):1487-1496.
 37. Tanchot C, Terme M, Pere H, Tran T, Benhamouda N, Strioga M, Banissi C, Galluzzi L, Kroemer G, Tartour E. Tumor infiltrating regulatory T cells: Phenotype, role, mechanism of expansion in situ and clinical significance. *Cancer Microenviron* 2013;6(2):147-157.
 38. van der Burg SH, Melief CJ. Therapeutic vaccination against human papilloma virus induced malignancies. *Curr Opin Immunol* 2011;23(2):252-257.
 39. Lim SN, Kuhn S, Hyde E, Ronchese F. Combined TLR stimulation with Pam3Cys and Poly I: C enhances Flt3 ligand dendritic cell activation for tumor immunotherapy. *J Immunother* 2012;35(9):670-679.
 40. Xiao H, Peng Y, Hong Y, Huang L, Guo ZS, Bartlett DL, Fu N, Munn DH, Mellor A, He Y. Local administration of TLR ligands rescues the function of tumor infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunization. *J Immunol* 2013;190(11):5866-5873.
 41. Nestle FO, Aljagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide or tumor lysate pulsed dendritic cells. *Nat Med* 1998;4(3):328-332.
 42. Schuler Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, Fritsch PO, Romani N, Schuler G. Rapid induction of tumor specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide loaded monocyte derived dendritic cells. *J Exp Med* 2002;195(10):1279-1288.
 43. Schuler G, Schuler Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. *Curr Opin Immunol* 2003;15(2):138-147.
 44. Waeckerle Men Y, Uetz von Allmen E, Fopp M, von Moos R, Bohme C, Schmid H P, Ackermann D, Cerny T, Ludewig B, Groettrup M, Gillessen S. Dendritic cell based multi epitope immunotherapy of hormone refractory prostate carcinoma. *Cancer Immunol Immun* 2006;55(12):1524-1533.
 45. Schliehe C, Redaelli C, Engelhardt S, Fehlings M, Mueller M, van Rooijen N, Thiry M, Hildner K, Weller H, Groettrup M. CD8 dendritic cells and macrophages cross present poly(D,L lactate co glycolate) acid microsphere encapsulated antigen in vivo. *J Immunol* 2011;187(5):2112-2121.
 46. Toledo H, Baly A, Castro O, Resik S, Laferte J, Rolo F, Navea L, Lobaina L, Cruz O, Miguez J, Serrano T, Sierra B, Perez L, Ricardo ME, Dubed M, Lubian AL, Blanco M, Millan JC, Ortega A, Iglesias E, Penton E, Martin Z, Perez J, Diaz M, Duarte CA. A phase I clinical trial of a multi epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non HIV 1 infected human volunteers. *Vaccine* 2001;19(30):4328-4336.
 47. Yu Z, Theoret MR, Touloukian CE, Surman DR, Garman SC, Feigenbaum L, Baxter TK, Baker BM, Restifo NP. Poor immunogenicity of a self/tumor antigen derives from peptide MHC I instability and is independent of tolerance. *J Clin Invest* 2004;114(4):551-559.
 48. Machlenkin A, Paz A, Bar Haim E, Goldberger O, Finkel E, Tirosh B, Volovitz I, Vadai E, Lugassy G, Cytron S, Lemonnier F, Tzehoval E, Eisenbach L. Human CTL epitopes prostatic acid phosphatase 3 and six transmembrane epithelial antigen of prostate 3 as candidates for prostate cancer immunotherapy. *Cancer Res* 2005;65(14):6435-6442.